Search
Research
National Hybrid Closed-Loop Outpatient TrialThe national Hybrid Closed-Loop Outpatient Trial will test the use of an automated insulin delivery system to see if it is better at optimising blood glucose levels than standard therapy.
Research Theme
Precision HealthUses personalised approaches to healthcare, aiming to tailor prevention and treatment strategies based on genetic, environmental, and lifestyle factors. This theme strives to make healthcare more targeted and effective for each child's unique needs.
The Adolescent Health and Wellbeing team works in partnership with young people to understand their priority needs and the best ways to address these. This includes informing evidence-based policies and co-designing accessible and responsive health services.
The Chronobiology team works to understand the factors that contribute to poor lung and heart function in newborn infants and find ways to prevent heart and lung disease.
Research
Western Australian DNA and Longitudinal Serum Bank for Weight RegulationThis resource will allow researchers to carry out studies which will look at the genetic causes of excessive weight gain and identify biomarkers
Research
The impact of Influenza infection during early life on immune developmentThis study will investigate the why disease is worse in infants and how early life viral infection impacts the developing immune system.
Research
Cystic Fibrosis Early Surveillance ProgramResearchers are able to track the progress of lung disease through a comprehensive longitudinal set of biological samples, images and data archives.
While COVID-19 is new and frightening, these resources are designed to help families tackle the challenges this virus has created for us.
Research
Respiratory Syncytial Virus (RSV)RSV hospitalises millions of babies worldwide every year: our research is helping to change that.
Research
Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling studyThe Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.